Nguyen
08-12-2023, 09:29 AM
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive (INTERIM) Results
https://www.businesswire.com/news/home/20230301005529/en/ACE-Breast-02-Pivotal-Phase-3-Study-of-Ambrx%E2%80%99s-ARX788-for-the-Treatment-of-HER2-Positive-Metastatic-Breast-Cancer-Achieves-Positive-Results
Emerging Data Behind 2 Antibody Drug Conjugates for Breast and
https://www.targetedonc.com/view/emerging-data-behind-2-antibody-drug-conjugates-for-breast-and-prostate-cancer
"...
This trial is a phase 2 study evaluating ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.
..."
https://www.businesswire.com/news/home/20230301005529/en/ACE-Breast-02-Pivotal-Phase-3-Study-of-Ambrx%E2%80%99s-ARX788-for-the-Treatment-of-HER2-Positive-Metastatic-Breast-Cancer-Achieves-Positive-Results
Emerging Data Behind 2 Antibody Drug Conjugates for Breast and
https://www.targetedonc.com/view/emerging-data-behind-2-antibody-drug-conjugates-for-breast-and-prostate-cancer
"...
This trial is a phase 2 study evaluating ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.
..."